Alliance enables customers to access and deploy validated COA instruments with unprecedented ease and support
HOBOKEN, NJ - Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence, announced today a collaboration with IQVIA, a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, that offers a one-stop, trusted solution to the Clinical Outcome Assessment (COA) implementation process - a solution that will save users significant time and effort.
This new alliance transforms COA accessibility, allowing pharmaceutical companies, research institutions and contract research organizations (CROs) worldwide to access validated COA instruments with unprecedented ease and end-to-end support. This one-stop approach streamlines the COA lifecycle, reducing vendor complexity, ensuring consistent quality, and improving support for use of every COA in line with regulatory and scientific standards.
Historically, managing COA licensing has required multiple vendor relationships, including coordination with publishers for instrument licenses, translation vendors for multi-language versions and consultants for scoring and implementation. This process can take months, delaying trial timelines and creating potential gaps in regulatory compliance and quality assurance. The Wiley-IQVIA collaboration shortens and simplifies this process, delivering a seamless, integrated solution for COA licensing and implementation through a single contract and from a rightsholder who can help maintain scientific integrity and copyright compliance.
Five Wiley-managed COA instruments are now available as end-to-end solutions in the first phase of the agreement, with plans to offer expanded access to Wiley's comprehensive portfolio, including more than 100 COAs, with full lifecycle support services for many established by the end of 2026.
The five instruments now available are:
- Hamilton Anxiety Scale (HAM-A)
- Hamilton Depression Rating Scale - 21-item (HAM-D21)
- Lansky Play-Performance Scale (LPPS)
- SLICC/ACR Damage Index
- Tanner Staging Scale
These instruments address critical domains in clinical research - from anxiety and depression to pediatric cancer functional status, lupus-related organ damage, and physical sexual maturity assessment.
The new collaboration combines Wiley's trusted academic publishing expertise with IQVIA's clinical implementation excellence, delivering scientifically rigorous COA solutions. Wiley provides access to validated instruments, with IQVIA expertise fully integrated to support translation, digital migration and implementation through one coordinated process. Translated versions will be available seamlessly through IQVIA's award winning eCOA platform.
"Pharmaceutical companies need absolute confidence in the scientific validity of their outcome measures, as patient outcomes, billions of dollars in R&D, and regulatory approval depend on it," said Jay Flynn, Wiley Executive Vice President and General Manager, Research & Learning. "Wiley's clinical outcome assessments are trusted by researchers worldwide for their scientific rigor. Through this collaboration with IQVIA, we're streamlining access to these validated instruments throughout the clinical trial lifecycle, accelerating the path from research to patient impact."
"Clinical outcome assessments are essential in both clinical and real-world research, serving as a regulatory standard for capturing and amplifying the patient's perspective on how they feel and function," stated Rob Kotchie, IQVIA, President of Real World Solutions. "IQVIA's advanced scientific and operational expertise in COA development and implementation can empower research teams to design and execute studies with efficiency and confidence. By partnering with Wiley on their extensive COA portfolio, we are directly expanding access to these capabilities for the drug and device development community, enabling faster, more reliable results that drive meaningful advancements in patient care."
The collaboration with IQVIA demonstrates Wiley's ability to integrate trusted research content into partners' clinical service platforms. It advances Wiley's broader strategic expansion into high-value corporate R&D markets, delivering the integrated, technology-enabled solutions pharmaceutical and biotech companies need.
To learn more about the expanded offering, visit this Wiley web page.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 91,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
